
Work Here?
Company Does Not Provide H1B Sponsorship
Elekta specializes in precision radiation medicine, delivering devices and software that help clinicians treat cancer and brain disorders. Its core products are radiation therapy equipment (such as linear accelerators and advanced radiosurgery platforms) and treatment-planning and clinical workflow software. These tools work together: the hardware delivers targeted ionizing radiation to tumors while imaging and planning software optimize dose exactly where it is needed, then guide clinicians through the treatment workflow. Elekta differentiates itself by offering an integrated hardware-software ecosystem with a global installed base, a focus on reaching underserved markets, and ongoing services to support clinicians and facilities. The company's goal is to improve patient outcomes by expanding access to high-quality radiation therapy and growing its installed base around the world.
Industries
Hardware
Enterprise Software
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Stockholms kommun, Sweden
Founded
1972
People at Elekta who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Paid Vacation
Hybrid Work Options
Wellness Program
Tuition Reimbursement
News details. Trade Compliance Case study: how Elekta transformed Carbon Compliance into a competitive advantage. Shruti Sharma Jun 10, 2026 As the European Union introduced the Carbon Border Adjustment Mechanism (CBAM), companies exporting carbon-intensive goods to the EU began facing new obligations related to embedded emissions reporting, data transparency, and carbon cost accountability. Elekta, operating in a globally integrated manufacturing and supply chain environment, required a structured and reliable mechanism to ensure full CBAM compliance for its EU-bound shipments. To meet these requirements, Elekta partnered with 4PL Consultancy Ltd. to establish a dedicated CBAM compliance support model. Acting as an extension of Elekta's trade compliance and sustainability teams, the 4PL function was responsible for end-to-end CBAM data management, emissions coordination, documentation validation, and reporting support. Today, the 4PL CBAM team manages the full compliance lifecycle - from supplier emissions data collection and validation to CBAM reporting readiness, emissions mapping, and stakeholder coordination ensuring that Elekta remains fully compliant with evolving EU regulations while maintaining supply chain efficiency. Client challenge. Elekta operates a complex global supply chain with manufacturing and sourcing activities spread across multiple countries, with significant exports into the European Union. With the introduction of CBAM, Elekta faced several key challenges: * New regulatory requirement to report embedded carbon emissions for EU-bound products * Lack of standardized emissions data across global suppliers * Difficulty aligning production data with CBAM reporting formats * Increased coordination between sustainability, logistics, and trade compliance teams * Need for supplier engagement across multiple geographies * Complex validation requirements for emissions calculations * Risk of non-compliance penalties due to inaccurate or incomplete data * High internal workload for managing CBAM readiness alongside existing compliance functions Without a structured system, managing CBAM obligations internally would have created significant operational and regulatory risk. The 4pl CBAM compliance solution. To address these challenges, Elekta implemented a dedicated CBAM compliance support model managed by 4PL Consultancy Ltd. The 4PL CBAM team functions as a centralized Carbon Compliance Control Tower, responsible for coordinating all CBAM-related activities across the supply chain. Rather than limiting its role to data collection, the 4PL team provides end-to-end CBAM governance, including: * Supplier emissions data collection and coordination * Embedded emissions calculation support (direct & indirect emissions) * CBAM data validation and consistency checks * Alignment of product-level data with EU CBAM reporting requirements * Cross-functional coordination between procurement, logistics, and sustainability teams * Preparation of CBAM reporting submissions * Audit-ready documentation management * Exception handling and discrepancy resolution * Ongoing regulatory tracking and advisory support This model transformed CBAM compliance from a fragmented internal process into a centralized, structured, and auditable compliance framework. End-to-end CBAM compliance management. 1. Supplier Engagement & Data Collection The CBAM process begins with structured engagement with Elekta's global supplier network. The 4PL team coordinates the collection of: * Production process emissions data * Energy consumption details * Material composition data * Manufacturing location-specific inputs * Supporting sustainability declarations Suppliers are guided to provide standardized CBAM-aligned datasets to ensure consistency across regions. 2. Embedded Emissions Mapping The 4PL team supports the classification and mapping of: * Direct emissions (manufacturing processes, fuel combustion, industrial operations) * Indirect emissions (electricity and purchased energy usage) This ensures that emissions are accurately categorized in line with CBAM methodology. 3. Data Validation & Quality Control Before submission, all emissions data undergoes structured validation checks, including: * Completeness of supplier data * Consistency with production volumes * Alignment with CBAM calculation methodology * Identification of data gaps or anomalies * Verification readiness assessment This significantly reduces the risk of rejection or audit issues. 4. CBAM Reporting Preparation The 4PL team prepares CBAM-ready reporting datasets, ensuring: * Structured formatting aligned with EU CBAM requirements * Product-level emissions attribution * Traceability of emissions sources * Documentation readiness for submission cycles 5. Compliance Coordination & Advisory Support In addition to data management, the 4PL team provides ongoing advisory support on: * CBAM regulatory updates and reforms * Reporting timelines and obligations * Interpretation of EU guidance documents * Risk identification and mitigation strategies * Internal alignment between business units Impact on Elekta's supply chain. The implementation of a dedicated CBAM 4PL support model delivered significant operational and compliance benefits: * Centralized and standardized emissions data management * Improved accuracy and consistency in CBAM reporting inputs * Reduced internal workload for sustainability and trade teams * Stronger supplier engagement and accountability * Enhanced readiness for regulatory audits and EU compliance checks * Reduced risk of penalties due to incomplete or inaccurate reporting * Faster and more structured CBAM reporting cycles Conclusion. CBAM represents a fundamental shift in global trade compliance, requiring companies to integrate carbon transparency directly into supply chain operations. Through its partnership with 4PL Consultancy Ltd., Elekta has successfully transitioned from a fragmented compliance approach to a centralized, structured, and scalable CBAM governance model. This enables Elekta to: * Maintain uninterrupted access to the EU market * Ensure regulatory compliance with CBAM requirements * Improve supply chain transparency and sustainability reporting * Build long-term readiness for future CBAM expansion across additional sectors Know first. Follow closely and receive content about our company and the news of the current market.
Elekta presents advancements in mr-guided radiotherapy at ESTRO 2026. By News Release Published Date: May 20, 2026 Recent research showcased at the European Society for Radiotherapy and Oncology (ESTRO) 2026 conference in Stockholm has emphasized significant strides in MR-guided adaptive radiotherapy across various cancer types. Elekta, the medical technology company, announced findings from over 120 studies by more than 30 international institutions, focusing on cancer treatments for breast, lung, pancreas, liver, kidney, and bladder, among others. The new data underscores the benefits of high-quality imaging paired with adaptive techniques in refining radiotherapy delivery. This approach may facilitate more precise and less invasive treatments that maintain clinical efficacy. John Christodouleas, MD, MPH, Elekta's Head of Medical Affairs and Partner Research, highlighted the value of seeing the targets during treatment, stating, "The emerging evidence at ESTRO demonstrates how this principle manifests in the everyday reality of clinical care." Prostate Cancer: Towards Shorter Treatments In a plenary session, the HERMES study from The Royal Marsden examined the use of two-fraction MR-guided radiotherapy for prostate cancer facilitated by the Elekta Unity MR-Linac. This technology allows clinicians to visualize the prostate and adjacent organs in real-time, adapting the treatment delivery - a crucial step when higher dose levels per session are involved. The study indicated favorable tolerability and the potential to drastically reduce the length of treatment protocols, which could lower the healthcare burden for patients. Rectal Cancer: Supporting Organ Preservation Research presented from the University of Tübingen's MARS protocol demonstrated that MR-guided adaptive radiotherapy using the Elekta Unity MR-Linac aids in organ preservation strategies in rectal cancer patients. Effective dose escalation and adaptive treatment approaches have shown high response rates, enabling the possibility of non-operative management without the need for immediate surgery and preserving bowel function. Liver Metastases: Enhanced Precision Treatments A comprehensive international analysis from the MOMENTUM and OligoCare registries focused on patients with liver oligometastases. It was noted that while stereotactic radiotherapy maintains strong tumor control, MR-guidance provides enhanced precision, potentially reducing the need for higher doses required by standard CBCT-guidance. This capability allows effective treatment delivery in challenging anatomical conditions, thereby improving the therapeutic ratio.
Elekta AB reported 2% revenue growth in Q3 2026, with gross margin improving 120 basis points to 38.3% and EBIT margin rising to 11.9%. The company achieved a book-to-bill ratio of 1.17, supported by strong momentum in Europe and growth in China. However, the quarter was significantly impacted by foreign exchange headwinds, with currency reducing net sales by over SEK500 million. The Americas region experienced a 6% sales decline. Elekta incurred restructuring charges exceeding SEK400 million but expects total costs under SEK500 million, with run-rate savings of over SEK500 million from Q1 next year. Net debt decreased by more than SEK200 million year-on-year. The company successfully launched Elekta Evo in the US and maintains leadership in China's underpenetrated radiotherapy market.
Elekta appoints Nexeva Healthcare Solutions as strategic partner in South Africa. Enhanced local service model to strengthen radiotherapy support, clinical capability and lifecycle management 3 Mar 2026 The agreement between Elekta and Nexeva Healthcare Solutions was formalised during the World Health Expo held in Dubai in February 2026. Back row (left to right): Ozgur Temel, head of sub-Saharan Africa at Elekta; Laurent Leksell, chairman of the board, Elekta; Marga Claassen, medical physicist and regional sales manager at Nexeva; Tomas Eliasson, vice chair of the board; Anthony Pedersen, CEO, Icon Healthcare Holdings. Front (seated): Simon Meredith, managing director Nexeva Healthcare Solutions; Feras Al Hassan, VP service and sales operations, Elekta. Elekta has appointed Nexeva Healthcare Solutions as its strategic partner in South Africa under a multi-year agreement. The appointment introduces a strengthened local operating model designed to enhance technical support, clinical engagement and commercial responsiveness for radiotherapy centres across both the private and public healthcare sectors. The agreement was formally signed during the World Health Expo in Dubai in February 2026, underscoring the strategic importance of the South African market within Elekta's broader regional framework. The signing brought together senior leadership from both organisations, reinforcing the long-term nature of the collaboration and its focus on strengthening radiotherapy delivery capacity across South Africa. Strengthening radiotherapy infrastructure. South Africa's oncology sector continues to operate under significant capacity pressure, where uptime, service responsiveness and access to clinical training are critical. The Elekta - Nexeva collaboration combines Elekta's global radiotherapy innovation and standards with Nexeva's established local healthcare footprint and service capability. Under the agreement, customers can expect: * Expanded field service engineering capacity in South Africa * Enhanced commercial and technical support * Closer clinical engagement, including applications and training support * Continued focus on installations, commissioning, upgrades and lifecycle management The partnership is structured to improve response times, strengthen local accountability and support long-term sustainability of radiotherapy services in the region. Elekta will maintain a lean, focused local team in South Africa, working in alignment with Nexeva to support customers and partners. Continuity of standards and patient safety. Elekta confirmed that equipment standards, quality systems and patient safety commitments remain unchanged. Nexeva will operate in full alignment with Elekta's global processes and performance standards, ensuring continuity across service, clinical support and commercial engagement. Simon Meredith, managing director at Nexeva Healthcare Solutions, said the appointment reflects a strategic commitment to strengthening oncology infrastructure in South Africa. "Radiotherapy centres operate in high-demand environments where reliability and rapid response are essential. This partnership enables us to combine Elekta's globally recognised technology with an agile, locally embedded support model that is responsive to the realities of South African healthcare." "Our priority is to work closely with clinical and technical teams to minimise downtime, strengthen capability through training and applications support, and ensure long-term lifecycle optimisation of installed systems." Meredith added that the collaboration is designed to support both immediate operational needs and future market development aligned to South Africa's radiotherapy priorities. Transition and implementation. Elekta and Nexeva have already engaged with customers to confirm commercial and technical points of contact, service pathways, escalation processes and alignment on planned installations, upgrades and training schedules. The multi-year agreement signals a long-term commitment to strengthening radiotherapy delivery capacity in South Africa, with a clear focus on service resilience, clinical partnership and sustainable growth. About elekta. As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com. About Nexeva Healthcare Solutions. Nexeva Healthcare Solutions is a South African healthcare solutions provider delivering innovative medical technologies and integrated support services. By combining trusted global innovations with agile local service, Nexeva supports healthcare providers in achieving optimal patient outcomes. Nexeva Health Solutions is a South African MedTech company committed to strengthening healthcare performance through high-quality technologies, responsive service, and clinical support. We partner with leading global manufacturers to bring proven innovations into the local market, ensuring clinicians have access to reliable, cost-effective solutions that enhance precision, efficiency, and continuity of care. Backed by Icon Healthcare's two-decade legacy in value-based care, Nexeva combines deep local expertise with a strong understanding of clinical workflows. Our team supports healthcare providers with integration, training, and ongoing technical service, expanding access to technologies that improve outcomes and enable sustainable, patient-centred healthcare across South Africa.
Elekta has received FDA 510(k) clearance for its Elekta Evo CT-Linac system, enabling its use across United States radiation oncology centres. The system combines high-quality CT imaging with linear accelerator functionality, allowing clinicians to visualise tumours and organs-at-risk more clearly during treatment. Evo features Iris, an AI-enhanced imaging capability that uses algorithms to minimise scatter and improve image reconstruction compared to traditional cone-beam CT imaging. The technology can be added as an upgrade to existing Elekta linear accelerators, extending their useful life whilst lowering adoption barriers. The system is already being used in Europe and other regions. Shares of Elekta rose 3.7% following the announcement, with the stock gaining 38.4% over the past six months.
Find jobs on Simplify and start your career today
Industries
Hardware
Enterprise Software
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Stockholms kommun, Sweden
Founded
1972
Find jobs on Simplify and start your career today